ERG and cancer: Our results that five epidriver candidates (SRCAP, EP400, ARID1B, MBD5, and KMT2A) among the top 15 ERGs enriched in EMT fraction (Fig. 5H; Supplemental Tables S6, S9) were found among the most mutated ERGs in clinical samples across cancer types (Fig. 2G) support the driver role of EMT-specific ERG tumorigenesis.